Hart LA, Phelan EA, Yi JY, Marcum ZA, Gray SL. Use of fall eisk-increasing drugs around a fall-related injury in older adults: a systematic review. J Am Geriatr Soc 2020;68:junio. [Ref.ID 103662]

Herman AO. NDMA found in extended-release metformin. Journal Watch 2020:2. [Ref.ID 103641]

Mathieson S, Lin C-WC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ 2020;369:28 de abril. [Ref.ID 103627]

Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]

Anderson TS, Odden MC, Penko J, et al.. Generalizability of clinical trials supporting the 2017 American College of Cardiology/American Heart Association blood pressure guideline. JAMA Intern Med 2020:16 de marzo. [Ref.ID 103580]

Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020:17 de febrero. [Ref.ID 103537]

Anónimo. Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA eequests withdrawal of weight-loss drug. U.S. Food and Drug Administration 2020:13 de febrero. [Ref.ID 103523]

Dimmitt SB, Stampfer HG. Polypill for prevention of cardiovascular diseases. Lancet 2020;395:413-4. [Ref.ID 103520]

Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:5 de febrero. [Ref.ID 103514]

Anónimo. Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin). FDA continues to evaluate the trial results. U.S. Food and Drug Administration 2020:14 de enero. [Ref.ID 103507]

Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 2020:1. [Ref.ID 103506]

Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLOS Medicine 0:9 de diciembre. [Ref.ID 103502]

Schuster BC, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018. PLOS Medicine 2019;16:10 de septiembre. [Ref.ID 103247]

Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics. A systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019;76:31 de julio. [Ref.ID 103245]

Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveern K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:29 de agosto. [Ref.ID 103243]

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. . Ann Intern Med 2019;171:248-56. [Ref.ID 103236]

Woodcock J. Statement from Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.. U.S. Food and Drug Administration 2019:5 de diciembre. [Ref.ID 103218]

Lee M, Sun J, Han M, Cho Y, Lee J-Y, Nam CM, Kang ES. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019;422:noviembre. [Ref.ID 103217]

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:21 de noviembre. [Ref.ID 103194]

Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:1. [Ref.ID 103193]